Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and 4-hydroxy-n-desmethyltamoxifen

lapatinib has been researched along with 4-hydroxy-n-desmethyltamoxifen in 1 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(4-hydroxy-n-desmethyltamoxifen)		Trials
(4-hydroxy-n-desmethyltamoxifen)		Recent Studies (post-2010) (4-hydroxy-n-desmethyltamoxifen)
1,9193051,44221518183

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)4-hydroxy-n-desmethyltamoxifen (IC50)
Estrogen receptorHomo sapiens (human)0.03
AromataseHomo sapiens (human)6.0333

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chan, EC; Chan, JC; Lim, P; Ong, PS; Teng, PX1

Other Studies

1 other study(ies) available for lapatinib and 4-hydroxy-n-desmethyltamoxifen

ArticleYear
Synergistic disruption of ERĪ±/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:1

    Topics: Activation, Metabolic; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Synergism; Estrogen Receptor alpha; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Tamoxifen

2017